2020
DOI: 10.1038/s41598-020-78492-y
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19 pneumonia and treated with canakinumab (300 mg sc). Median time from diagnosis of Covid-19 by viral swab to administration of canakinumab was 7.5 days (range 0–30, IQR 4–11). Median PaO2/FiO2 increased from 160 (range 53–409, IQR 122–210) at baseline to 237 (r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
42
0
1

Year Published

2021
2021
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 61 publications
(43 citation statements)
references
References 36 publications
0
42
0
1
Order By: Relevance
“…Tocilizumab (Actemra ® ) [25,[39][40][41][42][43][44] anti-IL-6 therapy Sarilumab (Kevzara ® ) [44][45][46] anti-IL-6 therapy Anakinra (Kineret ® ) [47] anti-IL-1 Therapy Canakinumab (Ilaris ® ) [48] anti-IL-1 Therapy Adalimumab (Humira ® ) [49,50] anti-TNF Therapy Infliximab (Remicade ® ) anti-TNF Therapy Baricitinib (Olumiant ® ) [ Tocilizumab is a humanised anti-human IL-6 receptor monoclonal antibody and an anti-rheumatic drug approved by the Japanese Government for rheumatic diseases such as RA, JIA and Takayasu arteritis [55]. Systemic JIA (sJIA) is one of the three subtypes of JIA, and adult Still's disease is thought to be an adult form of sJIA.…”
Section: Cessation Of Cytokine Stormsmentioning
confidence: 99%
See 1 more Smart Citation
“…Tocilizumab (Actemra ® ) [25,[39][40][41][42][43][44] anti-IL-6 therapy Sarilumab (Kevzara ® ) [44][45][46] anti-IL-6 therapy Anakinra (Kineret ® ) [47] anti-IL-1 Therapy Canakinumab (Ilaris ® ) [48] anti-IL-1 Therapy Adalimumab (Humira ® ) [49,50] anti-TNF Therapy Infliximab (Remicade ® ) anti-TNF Therapy Baricitinib (Olumiant ® ) [ Tocilizumab is a humanised anti-human IL-6 receptor monoclonal antibody and an anti-rheumatic drug approved by the Japanese Government for rheumatic diseases such as RA, JIA and Takayasu arteritis [55]. Systemic JIA (sJIA) is one of the three subtypes of JIA, and adult Still's disease is thought to be an adult form of sJIA.…”
Section: Cessation Of Cytokine Stormsmentioning
confidence: 99%
“…An observational, cohort, prospective study with 30 days of observation was conducted in patients hospitalised for COVID-19 pneumonia and treated with a single canakinumab dose. Although 13.6% of the patients died, 61.4% of cases experienced improved oxygen support [ 48 ]. Confirmation of the efficacy of canakinumab for COVID-19 requires further studies in randomised controlled trials.…”
Section: Treatments Of Cytokine Storms In Covld-19mentioning
confidence: 99%
“…Surprisingly, recent results of the Solidarity trial conducted in 30 countries worldwide revealed that many regimens have minor or no effect for treatment of hospitalized COVID-19 patients including remdesivir [34]. Therefore, the antiviral and immunotherapy agents required further testing of their efficacy in a larger population before any beneficial effect could be confidently announced [35][36][37][38].…”
Section: Therapeutics Guidelinesmentioning
confidence: 99%
“…Effectiveness of canakinumab has been suggested [38]. Canakinumab is a human anti-IL-1β monoclonal antibody developed by Novartis and at the end of 2020 it has been announced that canakinumab failed to improve survival in COVID-19 [39].…”
Section: Expression Of Cytokinesmentioning
confidence: 99%